Cleveland clinic researchers said Tuesday that conventional GLP -1 weight loss drugs, including Wegovy and Ozempic, may not be all in the “real world” environment.
The reason is that patients may take lower doses or discontinue their treatment, adversely affect the ability to control blood sugar in those who are prefixed.
Conclusions can affect people who are considering using drugs that more than eight million Americans use each year. They suggested an alternative to traditional and tax weight loss methods such as diet and fitness.
“Our study shows that patients treated with obesity semagluy or trizepatide have lost their average weight in a normal clinical environment compared to what is observed in randomized clinical trials,” said Cleveland clinic researcher dr. Hamlet Gasoyan. “According to our data, this can be explained by higher frequency of termination and lower doses used in clinical practice compared to randomized clinical trials.”
Gasoyan was the main author of the study published on Tuesday Obesity magazine;
Weight loss shots like Ozempic may not be available to everyone. Researchers of the Cleveland Clinic said the “real -world” test found that people had lost less weight in a normal clinical environment than in randomized clinical trials (Getty)
“Semaglutid has been thoroughly investigated in strong clinical development programs, in large real-world research and has more than 33 million patients’ exposure,” said Novo Nordisk spokesman. According to Novo Nordisk. Independent; “Semaglutide’s effectiveness and security has been detailed in comprehensive people with obesity/overweight strong evidence of how to improve health results. Semaglutid has shown the improvement of cardiovascular death, stroke and myocardial infarction.”
Eli Lilly’s comment request was not immediately returned Independent.
The study focuses on medicines with active substances semaglutid and thyzepatide; They include US food and drug administration approved type 2 diabetes medicines that are Zepbound and Mounjar. The authors examined their effects on weight loss and blood sugar levels in the real world. They noted that previous randomized clinical trials showed the effectiveness of those drugs.
The authors watched the health of nearly 7,900 adults who were very obese. More than 1,300 of them were pre -diabetes, starting with the onset of the study, and was at greater risk of developing type 2 diabetes: a chronic condition that affects the individual’s ability to use insulin and maintain blood sugar levels at normal levels. Participants were photographed from 2021 to 2023.
Researchers arranged patients who have stopped their obesity medicines to two groups: those who did it within three months and within three months to a year. The subsequent period of the investigation ended in December last year.
The most common cause of treatment in the real world was due to major drugs and insurance, side effects and deficiency. It is noteworthy that the cost of the study began to fall.
More than 20 percent of the participants stopped early and 32 percent discontinued the medication late. In addition, the authors noted that more than 80 percent of the lower dose needed to maintain the therapeutic effect. For Semaglutid it is equal to or less than 1 milligram and equal to or less than 7.5 milligrams of thyzepatide.
After a year of treatment, the average weight loss was 3.6 percent. Participants who have discontinued treatment early compared to 6.8 percent of those who have late treatment. However, those who did not interrupt the treatment and were the best dose lost the maximum weight of up to 13.7 percent. Semaglutide and 18 percent with tyrzepatide.
Participants were more likely to achieve 10 percent or greater weight loss after one year of treatment if they did not give up medication or so late (getty) (Getty)
Participants were more likely to achieve 10 percent or greater weight loss after one year of treatment, if they did not give up or delay their medication, were the highest doses needed for therapeutic effects, received thyzepatide and were women.
By monitoring blood sugar levels, those with diabetes, “researchers said only a third of those who had early treatment had normal blood sugar levels compared to 41 %, who discontinued treatment late and 67.9 %, who did not stop treatment.
Finally, the researchers noted that while patients who have discontinued obesity drugs lost significantly less weight compared to those who did not, their weight trajectories remained relatively stable. They said it would be the subject of additional research.
“Our conclusions could be informed of the real world models and related clinical results of the role of health care providers and their patients on the role of cessation and maintenance of the treatment for clinically significant weight loss,” Gasoyan explained.